Arterial Stiffness and Kidney Function

Hypertension

Volumn 43, Issue 2 I, 2004, Pages 163-168

  Safar, Michel E ^a   London, Gérard M ^b   Plante, Gérard E ^c  

^a HÔPITAL BROUSSAIS   (France)

^b Manhès Center   (France)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Arteries; Blood pressure; Hypertension; Kidney; Vascular

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHATE;

ARTERIAL PRESSURE; ARTERY CALCIFICATION; ARTERY COMPLIANCE; ARTERY STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRESS; VASCULAR RESISTANCE;

ADULT; ARTERIES; COMPLIANCE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; MODELS, CARDIOVASCULAR;

EID: 0842289475     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000114571.75762.b0     Document Type: Article

References (53)

1. Nichols WW, O'Rourke M. McDonald's blood flow in arteries. Theoretical, experimental and clinical principles, fourth edition. Sydney, Auckland: Arnold E: London; 1998:54-113, 201-222, 284-292, 347-401.
2. Guylon AC. Mean circulatory pressure, mean systemic pressure and mean pulmonary pressure and their effects on venous return. In: Guyton AC, Jones CE, eds. Circulation Physiology. Cardiac out-put and its regulation. Philadelphia: Saunders; 1963.
3. Guyton AC. Arterial pressure and hypertension. Circulatory physiology III. Philadelphia, Pa: WB Saunders; 1980:71-116, 293-334, 370-374.
4. Chau NP, Safar ME, London GM, Weiss YA, Levenson JA, Milliez PM. Essential hypertension: an approach to clinical data by the use of models. Hypertension. 1979;1:86-98.
5. Chau NP, Coleman TG, London GM, Safar ME. Meaning of the cardiac output-blood volume relationship in essential hypertension. Am J Physiol. 1982;243:R318-R328.
6. Safar ME, London GM, Levenson JA, Simon AC, Chau NP. Rapid dextran infusion in essential hypertension. Hypertension. 1979;1:615-623.
7. Safar ME, London GM. Arterial and venous compliance in sustained essential hypertension. Hypertension. 1987;10:133-139.
8. London GM, Safar ME, Levenson JA, Simon AC, Temmar MA. Renal filtration fraction, effective vascular compliance and partition of fluid volumes in sustained essential hypertension. Kidney Int. 1981;20:97-103.
9. Foley RN, Parfrey PS, Samak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
10. London GM, Guerin AP, Pannier B, Marchais SJ, Safar ME. Large artery structure and function in hypertension and end-stage renal disease. J Hypertens. 1998;16:1931-1938.
11. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50:600-608.
12. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:e10-e17.
13. Blumentahl HT, Lansing AI, Wheeler PA. Calcification of the media of the lumen aorta and its relationship to intimal arteriosclerosis, aging and disease. Am J Pathol. 1944;20:665-687.
14. Blacher J, Guerin A, Pannier B, Marchais S, Safar M, London G. Impact of aortic stiffness on survival in end-stage renal failure. Circulation. 1999;99: 2434-2439.
15. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992.
16. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M, London G. Increased stiffness of radial artery wall material in end-stage renal disease. Hypertension. 1997;30:1425-1430.
17. Acar C, Jebara V, Porthogese M. Comparative anatomy and histology of the radial artery and the internal thoracic artery: implication for coronary bypass. Surg Radiol Anat. 1991;13:283-288.
18. Amann K, Neusüb R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens. 1995;8:409-417.
19. Amann K, Wolf B, Nichols C, Törnig J, Schwartz V, Zeier M, Mall G, Ritz E. Aortic changes in experimental renal failure: hyperplasia or hypertrophy of smooth muscle cells? Hypertension. 1997;29:770-775.
20. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int. 2001;59:1834-1841.
21. Blacher J, Asmar R, Djane S, London G, Safar M. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111-1117.
22. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME. Aortic pulse wave velocity predicts cardiovascular mortality in subjects > 70 years of age. Arterioscler Thromb Vasc Biol. 2001;21:2046-2050.
23. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause mortality in hypertensive patients. Hypertension. 2001;37:1236-1241.
24. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886-891.
25. Yusuf S, Sleight P, Pogue J, Davies R, Dagenais G. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcome Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
26. PROGRESS Collaborative group. Randomized trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
27. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, Thomas F, Pannier B, Asmar R, Zureik M, Safar M, Guize L. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105: 1202-1207.
28. Van Bortel LM, Duprez D, Starmans-Kool MJF, Safar ME, Giannattasio C, Cockcroft JR, Kaiser DR, Thuillez C. Clinical applications of arterial stiffness Task Force III: recommendation for user procedures. Am J Hypertens. 2002;15:445-452.
29. Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerosis events. Arterioscler Thromb Vasc Biol. 2003;23:554-566.
30. Yip KP, Holstein-Rathlou NH, Marsh DJ. Chaos in blood flow control in genetic and renovascular hypertensive rats. Am J Physiol. 1991;261: F400-F408.
31. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res. 2002;90:1316-1324.
32. Pedrinelli R, Dell'omo G, Penno G, Bandinelli S, Bertini A, Di Bello V, Mariani M. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension. 2000;35:48-54.
33. Davies PF, Shi C, Depaola N, Helmke BP, Polacek DC. Hemodynamics and the focal origin of atherosclerosis: a spatial approach to endothelial structure, gene expression, and function. Ann NY Acad Sci. 2001;947:7-17.
34. Essig M, Terzi F, Burtin M, Friedlander G. Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells. Am J Physiol. 2001;281:F751-F762.
35. Plante GE, Alfred J, Chakir M. The blood vessel, linchpin of diabetic lesions. Metabolism. 1999;48:406-409.
36. Raghvendra KD, Jackson HD, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens. 1997;6:88-105.
37. Safar ME, Thuilliez C, Richard V, Benetos A. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res. 2000;46:269-276.
38. Safar M, Van Bortel L, Struijker-Boudier H. Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res. 1997; 81:34-67.
39. Blacher J, Amah G, Girerd X, Kheder A, Ben Maiz H, London GM, Safar ME. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10:1326-1334.
40. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar M, London G. Endothelin and cardiovascular remodeling in end-stage renal disease. Nephrol Dial Transplant. 1998;13:375-383.
41. Ruschitzka F, Corti R, Noll G, Lüscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens. 1999;17:S25-S35.
42. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule, JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension. 2000;36:330-336.
43. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats-effects of eplerenone. Circulation. 2002;106:2848-2853.
44. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H. Reactive glycosylaion end products in diabetic uremia and treatment of renal failure. Lancet. 1994;343:1519-1522.
45. Airaksinen KEJ, Salmela PI, Linnaluoto MK, Iläheimo MJ, Aloha K, Ryhänen LJ. Diminished arterial elasticity in diabetes: association with flourescent advanced glycosylation end products in collagen. Cardiovasc Res. 1993;27:942-945.
46. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138-151.
47. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI. Breakers of advanced glycation end-products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA. 1998;95:4630-4634.
48. Yu HCM, Burrel LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnstone CI. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation. 1998;98:2621-2628.
49. Et-Taouil K, Schiavi P, Levy BI, Plante GE. Sodium intake, large artery stiffness and proteoglycans in the SHR. Hypertension. 2001;38:1172-1176.
50. Et-Taouil K, Safar M, Plante GE. Mechanisms and consequences of large artery rigidity. Can J Physiol Pharmacol. 2003;81:205-211.
51. Plante GE. Vascular response to stress in health and disease. Metabolism. 2003;51:25-30.
52. Plante GE, Chakir M, Lehoux S, Lortie M. Disorders of body fluid balance: a new look into the mechanisms of disease. Can J Cardiol. 1995;11: 788-802.
53. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res. 2001;88:954-960.